AIM VACCINE(06660.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 122.82 million, loss narrowed by 6.33% YoY

NewTimeSpace (newtimespace.com) News,August 23, 2026, AIM VACCINE(06660.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 350.63 million, decreased by 31.87% YoY; Net Profit stood at loss of CNY 129.8 million, loss narrowed by 4.56% YoY; Profit Attributable to Shareholders stood at loss of CNY 122.82 million, loss narrowed by 6.33% YoY; Basic Earnings Per Share (EPS) stood at loss of CNY 0.1.
In terms of profitability, AIM VACCINE Gross Profit changed from CNY 341.24 million in the same period last year to CNY 245.77 million in the current period, decreased by CNY 95.47 million; gross profit margin changed from 66.3% in the same period last year to 70.09% in the current period, increased by 3.79 percentage points; net profit changed from loss of CNY 135.99 million in the same period last year to loss of CNY 129.8 million in the current period, increased by CNY 6.2 million; net profit margin changed from -26.42% in the same period last year to -37.02% in the current period, decreased by 10.6 percentage points.
In terms of earnings quality, AIM VACCINE Operating Profit changed from loss of CNY 123.19 million in the same period last year to loss of CNY 101.62 million in the current period, increased by CNY 21.58 million; Operating Profit Margin changed from -23.94% in the same period last year to -28.98% in the current period, decreased by 5.04 percentage points; Net Cash Flow from Operating Activities changed from cash outflow of CNY 96.84 million in the same period last year to cash inflow of CNY 1.02 million in the current period, increased by CNY 97.86 million; Ratio of Net Cash Flow from Operating Activities to Total Operating Revenue changed from -18.82% in the same period last year to 0.29% in the current period, increased by 19.11 percentage points.
In terms of financial soundness, AIM VACCINE Debt-to-Asset Ratio changed from 50.69% in the same period last year to 55.69% in the current period, increased by 5 percentage points; Total Equity changed from CNY 3.544 billion in the same period last year to CNY 2.807 billion in the current period, decreased by CNY 737.53 million; Cash and Cash Equivalents changed from CNY 289.507 million in the same period last year to CNY 169.518 million in the current period, decreased by CNY 119.99 million; Current Liabilities changed from CNY 3.03 billion in the same period last year to CNY 3.05 billion in the current period, increased by CNY 25.65 million; Quick Ratio changed from 0.59 in the same period last year to 0.49 in the current period, decreased by 0.1 percentage points.
In terms of R&D investment focus, AIM VACCINE R&D Expenses changed from CNY 106.96 million in the same period last year to CNY 48 million in the current period, decreased by CNY 58.96 million; R&D to Total Revenue Ratio changed from 20.78% in the same period last year to 13.69% in the current period, decreased by 7.09 percentage points.
By the close of trading on August 21, 2026, AIM VACCINE(06660) saw a loss of 5.29% in its share price, closing at HKD 1.61. The full-day turnover stood at HKD 711.64 thousand, with the latest market capitalization at HKD 817.35 million.

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.